Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...

Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...

Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly traded companies to bow to US President Donald Trump’s push against equal ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

Hoffmann–La Roche. Genentech, Inc. (a member of the Roche Group) and the University of Pittsburgh hold rights to IP related to this study. Marco Capogrosso, Genis Prat-Ortega and Mikael Eliasson hold ...

The trial was first announced in 2021. At that time, the researchers planned to use a different investigational drug - gantenerumab, by Roche/Genentech. However, Roche/Genentech discontinued the ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone receptors for estrogen and/or progesterone but lack HER2 overexpression. This ...